Chiesi Farmaceutici Acquires Amryt Pharma
Parma, Italy-based Chiesi Farmaceutici S.p.A. announced its acquisition of Amryt Pharma PLC (NASDAQ: AMYT) for $1.25 billion. Centerview Partners LLC served as exclusive financial advisor and Dechert LLP was the legal advisor to Chiesi. Moelis & Company LLC served as exclusive financial advisor and Cooley LLP and Gibson Dunn & Crutcher LLP were the legal advisors to Amryt. Amryt Pharma is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. It was founded in 2015 and is based in Dublin, Ireland. In 2022, the company reported revenue of $220 million. Chiesi... Read More »
Goldman Sachs Asset Management Acquires Norgine Europe B.V.
The private equity business within Goldman Sachs Asset Management has acquired Norgine Europe B.V. The deal is a milestone in Norgine’s history, following more than 110 years of ownership by the Stein family, which will continue to own a significant stake in the company. Terms of the deal were not disclosed. Norgine is a European specialty pharmaceutical company that has strived to deliver innovative medicines to patients for more than a century. Its European experience, fully integrated infrastructure and partnership approach allow it to apply solutions to bring patients medicines that they may not otherwise be able to access. Norgine helped 24 million patients around the world in... Read More »
Avenue Therapeutics Acquires Baergic Bio
Avenue Therapeutics, Inc. acquired Baergic Bio, Inc. in a deal involving two pharmaceutical companies. Terms of the transaction were not disclosed. Founded in December 2019, Baergic Bio is a clinical-stage company that focuses on the development of a pharmaceutical product for the treatment of neurological disorders. Avenue Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases. It is owned by Fortress Biotech, Inc. According to the LevinPro HC database, this was the 86th pharmaceutical deal of 2022. This compares with 42 pharmaceutical transactions that were reported between... Read More »
Fulgent Genetics Acquires Fulgent Pharma
Fulgent Genetics, Inc. (NASDAQ: FLGT) announced on November 7 that it acquired Fulgent Pharma Holdings, Inc. for approximately $100 million. Fulgent Genetics is a genetic testing company focused on transforming patient care in oncology, infectious and rare diseases and reproductive health. In 2021, the company reported revenue of $992.6 million for the entire year. Founded in 2011, Fulgent Pharma is an independent clinical-stage therapeutics development company focused on the development of cancer treatments. A special committee of Fulgent Genetics’ board of directors was advised by First Principles Advisory Group and Cooley LLP. Fulgent Genetics was represented in the... Read More »